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Background: Patients undergoing immune modulatory therapies for the treatment of autoimmune diseases such as
multiple sclerosis, and individuals with an impaired-immune system, most notably AIDS patients, are in the high risk
group of developing progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease of the white
matter caused by human neurotropic polyomavirus, JC virus. It is now widely accepted that pathologic strains of JCV
shows unique rearrangements consist of deletions and insertions within viral NCCR. While these kinds of
rearrangements are related to viral tropism and pathology of the disease, their roles in molecular regulation of JCV
gene expression and replication are unclear. We have previously identified SF2/ASF as a negative regulator of JCV gene
expression in glial cells. This negative impact of SF2/ASF was dependent on its ability to bind a specific region mapped
to the tandem repeat within viral promoter. In this report, functional role of SF2/ASF binding region in viral gene
expression and replication was investigated by using deletion mutants of viral regulatory sequences.
Results: The second 98-base-pair tandem repeat on Mad1 strain was first mutated by deletion and named
Mad1-(1X98). In addition to this mutant, the CR3 region which served the binding side for SF2/ASF was also mutated
and named Mad1-ΔCR3 (1X73). Both mutations were tested for SF2/ASF binding by ChIP assay. While SF2/ASF was
associated with Mad1-WT and Mad1-(1X98), its interaction was completely abolished on Mad1-ΔCR3 (1X73) construct
as expected. Surprisingly, reporter gene analysis of Mad1-(1X98) and Mad1-ΔCR3 (1X73) early promoter sequences
showed two and three fold increase in promoter activities, respectively. The impact of “CR3” region on JCV propagation
was also tested on the viral background. While replication of Mad1-(1X98) strain in glial cells was similar to Mad1-WT
strain, propagation of Mad1-ΔCR3 (1X73) was less productive. Further analysis of the transcription mediated by
Mad1-ΔCR3 (1X73) NCCR revealed that late gene expression was significantly affected.
Conclusions: The results of this study reveal a differential role of CR3 region within JCV NCCR in expression of JCV
early and late genes.
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Replication of the neurotropic JC virus in glial cells causes
the fatal demyelinating disease of the brain, progressive
multifocal leukoencephalopathy (PML), which is seen in
patients with underlying immunocompromised condi-
tions, notably among AIDS patients [1-3]. PML is the only
viral demyelinating disease of the human brain character-
ized by lytic infection of oligodendrocytes [4-6]. JCV in-
fects greater than 80% of the human population during
childhood, and establishes a latent infection in the kidneys* Correspondence: isariyer@temple.edu
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reproduction in any medium, provided the orand possibly in other body sites for the rest of the life
in healthy individuals [7,8]. Recently PML has been de-
scribed in patients with autoimmune diseases treated with
immunomodulatory therapies. The monoclonal antibodies,
natalizumab and efalizumab, are examples of these bio-
logical therapies. Natalizumab and efalizumab bind to
alpha-integrin molecules on the surface of B and T cells,
and prevent their entry into the brain. Another member of
immunomodulatory therapy, rituximab, binds to the CD20
molecule on the surface of B cells, causing their depletion
from peripheral circulation by activating the complement
cascade. During the clinical trial of Tysabri, PML has been
diagnosed in two multiple sclerosis patients and in one
Crohn’s patient [7,9,10]. As of March 1, 2012, 212 PMLd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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by Biogen Idec. 46 of these 212 patients with PML have
died. Currently, there is no specific therapy for the treat-
ment of PML. The non-coding control region (NCCR) of
JCV is ~ 400 bp and constitutes the so called archetype
form of the virus [11]. The Archetype strain of JCV is
found mostly in the kidney and urine of healthy individ-
uals. The NCCR region amplified from PML brain and
cerebrospinal fluid shows unique rearrangements gener-
ated by insertions and deletions compared to the archetype
strain [12], including the most studied PML type strain
(Mad-1) of the virus. The NCCR of the neurotropic strain
of JCV, Mad-1, is composed of two 98-bp tandem repeats
that have cell type-specific characteristics. Activation of
this region primarily occurs in glial cells such as oligoden-
drocytes and astrocytes [1,5]. Earlier studies established
that cell type-specific reactivation of JCV in glial cells is
primarily regulated at the transcriptional level [13]. We re-
cently identified the alternative splicing factor, SF2/ASF, as
a potential regulator of JCV whose overexpression in glial
cells strongly suppresses viral gene expression and replica-
tion [14]. Unexpectedly, down-regulation of JCV by SF2/
ASF is mediated at transcriptional stage, thus ascribing a
novel role for SF2/ASF in the control of promoter activity.
Results from a series of molecular and virological studies
indicated that SF2/ASF targets the JCV promoter and
strongly inhibits the JCV early and late gene transcription.
Accordingly, down regulation of SF2/ASF enhances the
level of viral gene expression and replication in astrocytic
cells. The suppression of JCV transcription by SF2/ASF
is accomplished through the interaction of SF2/ASF with
a unique DNA motif within JCV promoter region (CR3
region, ~25nt in length). Among the other polyomaviruses,
only the JCV promoter displays a binding motif for SF2/
ASF that is conserved between archetype strain and PML-
type strains (Mad1, Mad4). These observations placed
SF2/ASF in a unique position in which it showed a pro-
found ability to suppress replication and propagation of
JCV by specifically interfering with viral transcription.
Here we analyzed the viral transcription and replica-
tion mediated by JCV strains which partially or com-
pletely lacked SF2/ASF binding regions (CR3) within the
viral NCCR. Our results reveal a novel role of CR3 re-
gion in transcription mediated by the viral early and late
promoters.
Results
Interaction between SF2/ASF and JCV NCCR sequences
Archetype strain of JC virus is mostly identified in the
urine samples of healthy individuals pointing the kidneys
as the potential site for latent infection [15,16]. On the
other hand, archetype virus represents unique rearrange-
ments within NCCR region that creates new pathologic
strains identified in blood and CSF samples from PMLpatients [16-19]. The lack of archetype strain in the
brain of PML patients suggests that the virus requires
alterations in the NCCR region for the propagation of
the virus in the glial cells. The most studied pathologic
strain of JC virus (Mad1) consists of two 98-bp tandem
repeats (Figure 1A). We compared sequences of Mad1
and Archetype strains using the CLUSTAL sequence
alignment program. For the illustration purposes, each
98-bp tandem repeat was divided into four domains
(CR1, CR2, CR3, and CR4). As shown in Figure 1A,
there are multiple regions of sequence identity within
the first but not in the second 98-bp tandem repeat
of Mad1 and Archetype strains. Interestingly, archetype
strain represents only one binding site for SF2/ASF while it
was duplicated in Mad1 strain (Figure 1A, nucleotides in
red, CR3 region). In order to investigate importance of the
SF2/ASF binding domains, we first created a mutant NCCR
construct which lacked the second 98-bp tandem repeat
potentially serving only one binding site for SF2/ASF (JCV-
RR-(1X98). In the second construct, in addition to the sec-
ond 98-bp tandem repeat deletion, the CR3 region within
the first 98-bp tandem repeat was also mutated by deletion
and called JCV-RR-ΔCR3(1X73) (Figure 1B, upper panel).
We first designed a series of experiments to assess the
ability of SF2/ASF to bind the mutant-JCV promoter se-
quences. PHFA cells were transiently transfected with SF2/
ASF expression plasmid and pBLCAT3 plasmid constructs
containing the JCV-RR-WT, JCV-RR-(1X98), and JCV-RR-
ΔCR3 (1X73) NCCR sequences and interaction of SF2/
ASF with mutant viral sequences were analyzed by ChIP
assay as described in materials and methods. As expected,
ChIP analysis of PHFA cells demonstrated association of
SF2/ASF with JCV-RR-WT and JCV-RR-(1X98) mutant
promoter sequences (Figure 1B). Meanwhile SF2/ASF
showed no interaction with JCV-RR-ΔCR3 (1X73) pro-
moter (Figure 1B, lane 12) confirming that CR3 region was
mainly the site where SF2/ASF associated [14].
The second 98-bp tandem repeat and “CR3” region limit
JCV-early gene transcription
To determine the transcription mediated by JCV-early
promoter sequences from Mad1-WT, Mad1-(1X98), and
Mad1-ΔCR3 (1X73), promoter sequences were cloned
into CAT reporter plasmids. PHFA cells were transiently
transfected with these constructs and basal transcrip-
tional activities were determined by reporter gene assays
as described in the materials and methods. As shown
in Figure 2A, the reporter construct with one copy of
98-bp tandem repeat showed two fold higher transcrip-
tional activity than WT construct. More interestingly,
the third reporter construct [JCVE-RR-ΔCR3 (1X73)]
showed significantly higher transcriptional activities than
both JCVE-RR-(1X98) and JCVE-RR-WT. These results
suggested that the second 98-bp tandem repeat and CR3
AB
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Figure 1 (See legend on next page.)
Uleri et al. Virology Journal 2013, 10:147 Page 3 of 10
http://www.virologyj.com/content/10/1/147
(See figure on previous page.)
Figure 1 The “CR3” region within JCV NCCR is the target for SF2/ASF. A. Sequence alignment for the NCCR region of JCV. CLUSTAL
sequence alignment was performed for JCV Mad1 and Archetype strains (gene bank accession number NC_001699). The positions of replication
origin (ORI), CR1, CR2, CR3, CR4 and 98-bp-tandem repeats are illustrated in Mad1 strain. CR3 region is highlighted with sequences in red.
Numbering is relative to the Mad-1 strain of JCV. B. Upper panel: Schematic presentation of Mad1-WT, Mad1-(1X98), and ΔCR3-(1X73) promoter.
Arrows point the position of forward (PF) and reverse (PR) primers used in ChIP experiments. Lower panel: PHFA cells were transiently transfected
with pCGT7-SF2/ASF expression vector (SF2) or pCGT7 vector alone (vector) and pBLCAT3-JCV-RR-WT, pBLCAT3-JCV-RR-(1X98), and pBLCAT3-JCV-
RR-ΔCR3-(1X73) reporter plasmids. Cells were cross-linked and ChiP assay was performed using antibody to T7-tagged SF2/ASF (lanes 4 to 12). In
lanes 1, 2 and 3, pBLCAT3-JCV-RR-WT, pBLCAT3-JCV-RR-(1X98), and pBLCAT3-JCV-RR-ΔCR3-(1X73) reporter plasmid DNAs were used as positive
controls. C. Western blot analyzes of whole cell lysates from panel A (lanes 4 to 12), using specific antibodies against SF2/ASF and Tubulin.
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tion mediated by JCV-early promoter. Next, we analyzed
the effect of SF2/ASF on early gene transcriptional activity
mediated by mutant JCV-promoter sequences. As expected,
SF2/ASF suppressed transcription induced by the wild type
and the mutant [pJCV-RR-(1X98)] promoters (Figure 2B,
compare control, vector, and SF2 bars). As hypothesized,
SF2/ASF did not show any significant suppression on tran-
scription mediated by the JCV- ΔCR3 (1X73) promoter,
which lacked both “CR3” regions. These results suggest that
SF2/ASF binding to the JCV promoter through the CR3
region might be crucial for the suppression of viral early
gene transcription.
Propagation of JCV- Mad1 (1X98) and JCV-Mad1-ΔCR3
(1X73) strains in PHFA cells
Reporter gene analyses of mutant JCV promoter se-
quences (Figure 2A) suggested that CR3 region of JCV-
NCCR limits the early gene transcription of the virus.
However, these experiments were performed in the ab-
sence of viral early and late genes which might also in-
fluence the activity of viral transcription induced by wild
type and mutant viral constructs. In order to test the
possible impact of “CR3” region on viral propagation, same
promoter mutations in the reporter constructs (Figure 2A)
were also created on viral background. PHFA cells were
transfected/infected with these viral genomes as described
in materials and methods and whole cell extracts were an-
alyzed for the expression of viral early (LT-Ag) and late
genes (VP-1 and Agno) proteins at 7 and 14 days post-
infections. As shown in Figure 3B, the level of LT-Ag, VP-
1 and Agno protein expressions from the Mad1-WT and
Mad1-(1X98) gradually increased as the JCV infection
cycle reached 14d post-infection (lanes 1–4). Surprisingly,
the level of VP-1 expression from the Mad1-ΔCR3(1X73)
started markedly lower than Mad1-WTand Mad1-1X98 at
7d post-infections, and decreased dramatically at 14d post-
infections (Figure 3B, compare lanes 5–6 with lanes 1–4).
On the other hand, expression levels of LT-Ag and Agno
protein was undetectable in cellular extracts prepared
from the cells infected with the Mad1-ΔCR3(1X73) at day
14, and barely detectable for 7d post-infection (Figure 3B,
middle panel, lanes 5–6). Since viral gene expression is
negatively affected in the Mad1-ΔCR3 (1X73) infections,we next assessed the functional consequences of this effect
on viral DNA replication by employing a Dpn I replication
assay in parallel to western blot analysis of viral genes.
Subsequently, newly replicated Dpn I- resistant DNA was
analyzed by Southern blotting. It was observed that the
replication efficiency of the Mad1-ΔCR3 (1X73) was much
lower than Mad1-WT and Mad1-(1X98) (Figure 3C). JCV
particles in growth medium of infected cells were also
analyzed and quantified by Q-PCR analysis at 14d post-
infections. As shown in Figure 3D Mad1-ΔCR3-(1X73)
showed significantly lower levels of viral copies in growth
media as compared with Mad1-WTand Mad1-(1X98).
JCV-Mad1-Mut.CR3-(1X73) is defective in late
gene transcription
Mutational analyses of the second 98-bp tandem repeat
and CR3 region within JCV promoter suggested that JCV-
Mad1- ΔCR3(1X73) showed two and three fold higher
transcriptional activity for the early genes than JCV-Mad1-
(1X98) and JCV-Mad1-WT, respectively (Figure 1B). Un-
expectedly, propagation of JCV-Mad1- ΔCR3-(1X73) was
insufficient in PHFA cells (Figure 3). JCV-NCCR is a bi-
directional promoter which simultaneously encodes early
and late genes. The observed defect in replication of JCV-
Mad1- ΔCR3-(1X73) suggested that late gene expression
could be affected by the applied mutations within the viral
promoter. To determine the transcription mediated by
JCV-late promoters, Mad1-WT, Mad1-(1X98), and Mad1-
ΔCR3 (1X73) NCCRs were cloned into a CAT reporter
construct in late orientations (Figure 4A). PHFA cells were
transiently transfected with these constructs and basal
transcriptional activities were determined by CAT assay.
As shown in Figure 4, the Mad1-WT and Mad1-(1X98)
showed comparable transcriptional activities. However, the
third reporter construct with no CR3 region [Mad1- ΔCR3
(1X73)] showed significantly lower transcriptional activity
than Mad1 WT and Mad1-(1X98). These results suggest
that the “CR3” domain within the first 98-bp tandem re-
peat was critical for the expression of viral late genes.
Discussion
JCV infects human population in childhood and estab-
lishes a persistent latent infection for the rest of the life.
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Figure 2 Transcriptional activities of mutant JCV promoter sequences. A. Cat enzyme activity of JCV-early promoter constructs were detected,
and presented as bar graph. Schematic representation of JCV NCCR sequences cloned into CAT reporter constructs in early orientations was shown at
the top of the graph. B. Effect of SF2/ASF on transcription induced by mutant JCV promoter sequences. pBLCAT3-JCVE-RR WT, pBLCAT3-JCVE-RR-(1X98),
and pBLCAT3-JCVE-RR- ΔCR3-(1X73) reporter plasmids were transiently transfected into PHFA cells in the presence or absence of either pCGT7 vector
alone or pCGT7-SF2/ASF expression plasmid. Cat enzyme activity of JCV promoter constructs were detected, and presented as bar graph.
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NCCR. On the other hand, the JCV genome in CFS sam-
ples from PML patients show rearranged NCCRs involv-
ing deletions and insertions within this region, suggesting
that the archetype strain of the JCV is not able topropagate in the brain without the proper rearrangements
[18,19]. While these kinds of rearrangements are related
to viral tropism and pathology of the disease, their roles in
molecular regulation of the JCV gene expression and rep-
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Figure 3 Viral propagation of mutant JCV strains in PHFA cells. A. Schematic representation of JCV wild type and mutant genomes. B. Western
blot analyzes of whole cell extracts from PHFA cells infected with JCV-Mad1-WT and mutants, JCV-Mad1-(1x98), and JCV-Mad1-ΔCR3-(1X73), using
specific antibodies against LT-Ag, VP1, SF2/ASF and Agno protein. In lanes 7 and 8, whole cell extracts from uninfected cells were loaded as negative
control. Western blot analyzes of same extracts with anti-Grb2 antibody was used as loading control. DPI depicts “day post-infection”. C. Southern blot
analyses of replicated JCV genomic DNAs in parallel to protein samples in panel A. In lanes 1, 2 and 3, 2 ng of linearized Mad1-WT, Mad1-(1X98), and
Mad1-ΔCR3-(1X73) were used as positive controls, respectively. In lane 4, DNA samples from uninfected cells were loaded as negative control. D. Q-PCR
analyses of the JCV copy numbers in growth media of the infected PHFA cultures. Culture media was collected at 14 dpi, and was processed for the
detection of viral particles by Q-PCR as described earlier [12,16].
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ASF, a cellular alternative splicing factor, targets a unique
sequence within JCV NCCR and strongly inhibits viral
transcription and viral propagation in glial cells [14]. Here
we created mutant viral strains, which partially or totally
missing SF2/ASF binding domains, on the Mad1 strain, a
rearranged viral strain isolated from a patient’s brain with
PML which consists of two 98-bp tandem repeats within
the viral NCCR and contains two binding sites for SF2/
ASF. In the first construct we deleted the second 98-bp
repeat and investigated the impact of this large deletion
on viral transcription and replication by reporter gene
analysis and viral propagation assays. While the Mad1
genome with only one 98-bp tandem repeat showed more
than two fold higher early transcriptional activity than
wild type promoter, it only showed a slight increase in the
late gene transcriptional activity. The mutant strain with
only one 98-bp tandem repeat is highly relevant to the
clinic since there have been same viral strains isolated
from patients with colon cancer. Interestingly, JCV Mad1
strain was isolated in colon cancer tissue, and the variantwith 98-bp tandem repeat deletion was exclusively found
in these cancers [20]. Our results suggest that deletion of
one 98-bp tandem repeat within the Mad1 NCCR in-
creases the rate of early gene transcription which express
viral tumor antigens, large T-Ag and small t-ag, and may
suggest a possible mechanism for the involvement of JCV
in the formation of colon cancers. Whether the Mad1
strain with one 98-bp tandem repeat will show higher
early gene expression in colon cancer cells needs to be
clarified and possible involvement of this strain in human
colon cancer development needs to be further investi-
gated. In addition to deletion of the second 98-bp tandem
repeat, we also created a viral construct with no binding
site for SF2/ASF [JCV-Mad1-ΔCR3 (1X73)] in which the
CR3 region within the first 98-bp repeat was also mutated
by deletion. While early transcription was significantly in-
creased by the Mad1-ΔCR3 (1X73) NCCR, there was a
dramatic decrease in the levels of viral replication. Further
analyses of the transcription mediated by Mad1-ΔCR3
(1X73) NCCR revealed that late gene expression was sig-
































Figure 4 The “CR3” region within JCV NCCR is critical for the expression of late genes. Cat enzyme activity of JCV-late promoter constructs
were detected, and presented as bar graph. Schematic representation of JCV NCCR sequences cloned into CAT reporter constructs in late
orientations was shown at the top of the graph.
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glial cells. One could argue that removal of the CR3 region
along with second 98-bp tandem repeat would disrupt the
transcriptional initiation for the late genes. Western blot
analysis of the protein extracts from glial cells infected
with Mad1-ΔCR3 (1X73) revealed that major capsid pro-
tein VP1 expression was detectible at 7 day post infections
suggesting that late gene transcription was successfully
initiated. However, protein expression levels were much
lower than either Mad1-WT or JCV-Mad1-(1X98). One
possible explanation for the decreased levels of late gene
expression could be the transcription factors which bind
to the CR3 region to enhance the late gene transcription.
This region encompasses predicted binding sites for several
transcription factors including Purα, NF-1, MF3, Elk-1,
COE1, and p300. The importance of these transcription
factors and their interaction with SF2/ASF for the regula-
tion of JCV late gene transcription remains to be investi-
gated. It was surprising to observe that LT-antigen
expression was reduced in cells infected with JCV-Mad1-
ΔCR3 (1X73), because of the early promoter activity of
this viral strain was much higher than Mad1-WT and
Mad1-(1X98). One possible explanation of the reduced
levels of LT-ag expression could be due to the auto-
regulation of the protein. LT-antigens of polyomavirusesare well known as auto-regulatory proteins [21] and viral
NCCR sequences have shown to be important for the
autoregulation of the protein [22,23], Low levels of LT-ag
expression by JCV-Mad1-ΔCR3 (1X73) virus at 7 dpi infec-
tion could be due to the alteration of this autoregulation.
Alternatively, our data indicated that JCV-Mad1-ΔCR3
(1X73) construct was less efficient for the late gene tran-
scription. The observed low levels of LT-ag could also be
due to the inefficient late gene transcription since that was
resulted in a dramatic decrease of viral propagation.
Conclusions
The aim of this study was to investigate the role of SF2/
ASF binding region in JC virus gene expression and rep-
lication by using deletion mutants of viral regulatory
sequences. Reporter gene analyses of Mad1 promoter se-
quences with mutations either partially or totally lacking
SF2/ASF binding regions showed a significant increase
in early promoter activities suggesting that SF2/ASF
binding region (CR3) put a negative pressure on viral
early transcription. Following results from viral propaga-
tion and reporter gene studies suggested that the CR3
region was crucial for the propagation of the virus and
the transcription of late genes in glial cells. The results
of this study suggest a novel role of the second 98-bp
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repeat of JCV promoter in transcription mediated by the
viral early and late promoters.
Methods
JCV strains and plasmid constructs
The wild type Mad1 strain of JCV was linearized by
BamH1 digestion, and cloned into the pBlueScript KS
(+) vector previously [14]. To mutate the second 98 bp
repeated region on JCV promoter, the pBlue-Mad1-WT
construct was digested with Avr II restriction enzyme
which cut viral genome once within 98 bp repeat regions.
The digested product was gel purified, re-ligated, se-
quenced, and named as pBlue-Mad1-(1X98). The pBlue-
JCV-Mad1-ΔCR3(1X73) construct which lacked the CR3
region within the 98-bp-repeat, was created from pBlue-




product was gel purified, ligated, and sequenced. pBLC
AT3-JCV-RR-WT reporter construct was described previ-
ously [24]. Reporter gene constructs containing the regula-
tory region of the JCV Mad1-(1X98) and JCV-Mad1- ΔCR3
(1X73) were created as follows. Mad-1 (4987–240) region
was PCR-amplified using appropriate primers from Mad1-
(1X98) and Mad1- ΔCR3 (1X73) templates and was in-
serted into Bam HI site of pBLCAT3 vector in early (E)
and late (L) orientations. The resulting reporter plasmids
were called pBLCAT3-JCV-RR-(1X98) and pBLCAT3-JCV-
ΔCR3(1X73. pCGT7-SF2/ASF-FL expression plasmid was
a kind gift from Dr. Javier F. Ca’ceres (Medical Research
Council Human Genetics Unit, Western General Hospital,
Edinburgh EH4 2XU, Scotland, United Kingdom).
Cell lines
Primary human fetal astrocytic cells (PHFA) were pre-
pared as previously described [25]. Briefly, human fetal
brain tissue was obtained from Advanced Biosciences
Resources, Inc. (Alameda, CA). The tissue was washed
with HBSS medium and placed in a 100 mm dish. Blood
vessels and meninges were dissected, and tissue was cut
into small pieces using a forceps and scalpel. Chopped-
tissue was mechanically disrupted by pipetting up and
down in HBSS with a 10 ml pipette until cell culture
fluid smooth and pinkish in color. The tissue was cen-
trifuged and digested with DNAse I and trypsin in 10 ml
HBSS medium for 30 minutes at 37 0C. Cells were
washed with HBSS and passed through a 70-micron fil-
ter. Mixed cultures of glial cells were plated in Poly-D-
Lysinized T162 cm 2 flasks with DMEM/F12 medium
(1/1) containing 10% FBS, 1% L-glutamine, 1% Fungizone,
insulin, and gentamycin. After plating 4–5 days, the cells
were washed with PBS and trypsinized. They were thenplated in T162 cm 2 flasks and incubated for 45 minutes.
During the 45 minute period, microglial cells attached to
the flask, and most of the astrocytes, neurons, and oligo-
dendrocytes remained in the medium. After 45 minute
incubation, the medium was removed and placed in new
flasks. The cells were grown in culture until they were
confluent. Once confluent, the cells were placed on an
orbital shaker to remove the neurons and oligodendro-
cytes, which detached from the surface of the flasks and
came off into the medium. After proper shaking, the
medium was replaced with astrocyte growth medium,
DMEM/F12 (1/1) with 15% FBS, 1% L-glutamin, insulin,
and gentamycin.
ChIP assay
PHFA cells were transiently transfected with pBLCAT3-
JCVE-RR-WT, pBLCAT3-JCVE-RR-(1X98), and pBLCAT3-
JCVE-RR-(Mut.CR3) reporter constructs in the presence or
absence of pCGT7-SF2/ASF expression plasmid. ChIP as-
says were performed at 72 h post-transfections as described
previously [14]. Briefly, proteins were cross-linked to DNA
by formaldehyde, following by sonication to fragment the
chromatin and immunoprecipitation of specific proteins to
obtain DNA segments. Cross-linking was reversed and
DNA was analyzed by PCR.
Transcription assay
Chloramphenicol acetyltransferase (CAT) assay was per-
formed as described before [14,24]. Briefly, PHFA cells
were plated in 60 mm tissue culture dishes and transiently
transfected with pBLCAT3-JCV-RR-WT, pBLCAT3-JCV-
RR-(1X98), and pBLCAT3-JCV-RR-ΔCR3 (1X73) reporter
constructs in the presence or absence of pCGT7-SF2/ASF
expression plasmid. At 48 h post-transfection, cells were
extracted with a series of freeze/thaw cycles, and the CAT
activity of the samples was determined.
JCV infection
Transfection/infection of cells with the full-length JCV
Mad-1 genome was described previously [14,24,26]. Brief-
ly, pBlue-Mad1-WT pBlue-Mad1-(1X98) and pBlue-JCV-
Mad1-ΔCR3 (1X73) were digested with BamH1 enzyme
to remove the complete viral genomes from pBlue.Script
KS (+) plasmid. PHFA cells, at a confluence of 1 × 106 cells
per T75-cm tissue culture flask, were co-transfected/
infected with the JCV-Mad1-WT, JCV-Mad1-(1X98), and
JCV-Mad1-(Mut.CR3) DNA (10 μg/flask) using Fugene6
transfection as indicated by the manufacturer (Roche). At
12 days post-infection, cells were trypsinized and split into
two equal portions. One half was used for preparation
of whole cell protein extract for Western blot analysis,
and the other half was used for DNA preparation using
Qiaprep Spin Miniprep kit (Qiagen).
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Replication assays were carried out as previously described
[14,24]. Briefly, PHFA cells (1 × 106 cell/75 cm2 flask) were
transfected/infected as described above. Low molecular
weight DNA purified from JCV-infected cells was digested
with Dpn I and BamH1 enzymes [27]. Digested-DNA
samples were separated on 1% agarose gel and were trans-
ferred to a nylon membrane. Replicated viral DNA was
visualized upon incubation of the membrane with a [32P]-
labeled JCV DNA probe as described earlier [14].
Quantitative-PCR (Q-PCR) analyses of JCV copy numbers
in growth media
Transfection/infection of cells with the full-length JCV-
Mad1 genome was performed as described above. The
culture medium (containing viral particles) was collected
at 12 days post-infection, and after centrifugation at
13,000 rpm for 10 minutes to remove cell debris, super-
natants were collected and incubated at 95°C for 10 mi-
nutes to inactivate virus. Ten microliters of the medium
was then used as a template in Q-PCR reactions. The
standard curve was obtained after serial dilution of pJCV, a
plasmid containing the whole genome of the JCV Mad-1
strain. The standard curve was then used to extrapolate
the viral load of each sample. Negative and positive con-
trols were included in each reaction and each sample was
tested in triplicate. All Q-PCR analyses were done by using
Light cycler 480 (Roche). Primers were JCV Q-PCR-for-
ward: 5’-AGTTGATGGGCAGCCTATGTA-3’ and JCV Q-
PCR-reverse: 5’- TCATGTCTGGGTCCCCTGGA-3’. The
probe for the Q-PCR was 5’-/5HEX/CATGGA TGCTC
AAGTAGAGGAGGTTAGAGTTT/3BHQ_1/-3’.
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